From: Benefits and harms of medical cannabis: a scoping review of systematic reviews
Author, year {refid} | Search dates; # databases searched | Funding source | Nstudies | Illness/condition | Intervention/comparator | Outcomes | Conclusions from data | AMSTAR-2 rating |
---|---|---|---|---|---|---|---|---|
Baldinger, 2012 [50] | To Jan 2011 and Cochrane specialized register to Feb 14, 2011; 4 | Non-profit | 1 | ALS/motor neuron disease | I: Plant-derived cannabinoids C: Placebo | • Muscle cramps • Muscle cramps as AEs | No statistically significant difference between groups | L |
Gloss, 2014 [72] | Searched on Sept 9, 2013; 6 | NR | 4 | Epilepsy | I: Plant-derived cannabinoids C: placebo | • Seizure freedom for 12 months | No studies assessed primary outcome in this review | M |
Krishnan, 2009 [59] | Dec 2005–Apr 2008; 6 | NR | 1 | Dementia | I: Synthetic cannabinoids C: Placebo | • Body weight • Triceps skinfold thickness • Disturbed behavior • Affect | Only one study included | L |
Hanson, 2011 [74] | Jan 1990 to Oct 2009; 5 | Government | 1 | Dementia | I: Synthetic cannabinoids C: placebo | • Weight • Negative affect • Disruptive behavior | Only one study included | L |
CADTH, 2018 [83] | Jan 1 2012 to Nov 29, 2017; 6 | No funding | 4 | Dementia | I: Plant-derived cannabinoids C: Placebo | • Static balance • Dynamic balance • Stride length • Total AEs • Dizziness • Somnolence • Balance disorders • Falls • Severe AEs | Only one study included | CL |